ginkgolide b has been researched along with triazolam in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (25.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cavero, I; Durand, G; Floch, A; James, C; Lave, D; Le Fur, G; Mondot, S; Pacot, D; Robaut, C; Sedivy, P | 1 |
Kishore, K; Saraf, MK; Sharma, A; Singh, M; Thomas, KM | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
4 other study(ies) available for ginkgolide b and triazolam
Article | Year |
---|---|
PAF binding sites. Characterization by [3H]52770 RP, a pyrrolo[1,2-c]thiazole derivative, in rabbit platelets.
Topics: Animals; Blood Platelets; Diterpenes; Furans; Ginkgolides; In Vitro Techniques; Kinetics; Lactones; Male; Plant Extracts; Platelet Activating Factor; Platelet Aggregation; Platelet Membrane Glycoproteins; Pyridines; Rabbits; Radioligand Assay; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Stereoisomerism; Thiazoles; Triazolam; Tritium | 1987 |
Role of platelet activating factor in triazolobenzodiazepines-induced retrograde amnesia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Amnesia, Anterograde; Amnesia, Retrograde; Animals; Anti-Anxiety Agents; Azepines; Diazepam; Diterpenes; Escape Reaction; Female; Flumazenil; Ginkgolides; Lactones; Learning; Male; Mice; Phospholipases A; Platelet Activating Factor; Platelet Membrane Glycoproteins; Reaction Time; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, GABA-A; Retention, Psychology; Triazolam | 2003 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |